| View |
|
BR-1059
|
Somatropin
|
Scitropin A
|
5 mg/ 1.5 mL (15IU)
|
Solution S.C. for Injection
|
Prescription Drug (RX)
|
USP Type I Clear and Colourless Glass Cartridge x 1.5mL (Box of 1's and 2's)
|
Anterior Pituitary Lobe Hormone and Analogue
|
SANDOZ GmbH
|
Austria
|
|
Metro Drug, Inc.
|
Metro Drug, Inc.
|
Renewal
|
01 November 2023
|
27 November 2028
|
| View |
|
BR-1068
|
Trastuzumab
|
Herceptin
|
150 mg
|
Lyophilized Powder For Concentrate Solution For Infusion (IV)
|
Prescription Drug (RX)
|
Colourless glass vial (Box of 1's)
|
-
|
Genentech, Inc.
|
United States of America
|
F. Hoffmann-La Roche Ltd.
|
Roche (Philippines) Inc.
|
Zuellig Pharma Corporation
|
Initial (Variation)
|
11 October 2022
|
11 October 2027
|
| View |
BR-1072_PI_01.pdf
|
BR-1072
|
Ranibizumab
|
Lucentis
|
10 mg/mL
|
Solution For Injection (Intravitreal)
|
Prescription Drug (RX)
|
2mL USP Type I Clear glass vial + CE-Marked medical device (5 µm filter needle) in a box
|
Antineovascular agents
|
Novartis Pharma Stein AG
|
Switzerland
|
|
Sandoz Philippines Corporation
|
|
Renewal
|
31 May 2024
|
29 May 2029
|
| View |
|
BR-1073
|
Filgrastim
|
Neubicyte
|
150 mcg/mL
|
Solution for Injection/ 150mg/ml
|
Prescription Drug (RX)
|
1ml
|
Hematopoietic Growth Factor
|
Harbin Pharmaceutical Group Bioengineering Co., Ltd.
|
China
|
|
Endure Medical, Inc.
|
Endure Medical, Inc.
|
Renewal
|
20 June 2022
|
26 May 2027
|
| View |
BR-1084_PI_01.pdf
|
BR-1084
|
Quadrivalent Seasonal Influenza Vaccine (Split)
Virion, Inactivated) 2024 Southern Hemisphere Strain.
|
Fluquadri
|
Formulation:
Each dose (0.5 mL) contains the following influenza strains*:
A/Victoria/4897/2022 (H1N1) pdm09-like strain
15 μg of HA**
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
15 μg of HA**
(A/California/122/2022, SAN-022)
B/Austria/1359417/2021-like strain
15 μg of HA**
(B/Michigan/01/2021, wild type)
B/Phuket/3073/2013 (B/Yamagata lineage)-like virus
15 μg of HA**
(B/Phuket/3073/2013, wild type)
*Propagated in embryonated chicken eggs
|
Suspension for Injection (IM)
|
Prescription Drug (Rx)
|
0.5 mL in 1.5 mL USP Type I borosilicate pre-filled glass syringe with bromobutyl plunger stopper, luer- lock adapter, and tip cap (Box of 5's).
|
Vaccines
|
Sanofi Pasteur
|
U.S.A
|
|
Sanofi Pasteur, Inc.
|
Zuellig Pharma Corporation
|
Monitored Release (Strain Clearance)
|
05 April 2024
|
05 April 2025
|
| View |
|
BR-1091
|
Epoetin beta
|
Recormon
|
2,000 I.U./0.3mL
|
Solution for Injection (S.C./I.V.)
|
Prescription Drug (Rx)
|
Pre-filled syringe of 0.3 mL with needle 27G ½" (Box of 6's)
|
Antianemic Preparations
|
Roche Diagnostic GmbH
|
Germany
|
|
Roche (Philippines), Inc.
|
Zuellig Pharma Corporation
|
Renewal
|
18 September 2021
|
05 November 2026
|
| View |
|
BR-1093
|
Alteplase
|
Actilyse
|
50 mg
|
Powder for Solution for Infusion (IV
|
Prescription Drug (RX)
|
Each box contains: Ph. Eur. Type I colourless glass vial
with bromobutyl rubber stopper and aluminium/ polypropylene, dark green flip-off seal + Type I glass vial (Sterile Water for Injection as diluent) x 50 mL
|
-
|
Boehringer Ingelheim Pharma GmbH & Co. KG
|
Germany
|
N/A
|
Boehringer Ingelheim (Philippines), Inc.
|
Boehringer Ingelheim (Philippines), Inc.
|
Initial (Variation)
|
19 September 2022
|
19 September 2027
|
| View |
BR-1101_PI_01.pdf
|
BR-1101
|
Tocilizumab
|
Actemra
|
162 mg/ 0.9 mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
Packaging: 0.9 ml Solution in 1 ml Pre-Filled Syringe (Type I Glass) with a Staked-in Needle. The syringe is closed by a Rigid Needle Shield (Elastomer Seal with a Polypropylene Shell) and a Plunger Stopper (Butyl Rubber with a Fluororesin Coating) (Box of 1's and 4's).
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
|
Roche (Philippines), Inc.
|
Zuellig Pharma Corporation
|
-
|
08 March 2022
|
28 July 2025
|
| View |
|
BR-1121
|
Trastuzumab
|
Herceptin
|
600 mg/ 5 mL (120 mg/ mL)
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
6 mL (Net content: 5 mL)Type I clear glass vial with butyl rubber stopper laminated with a fluoro-resin (Box of 1's)
|
-
|
F. Hoffmann-La Roche AG
|
Switzerland
|
N/A
|
Roche (Philippines) Inc.
|
Roche (Philippines) Inc.
|
Regular Renewal (Compliance)
|
07 March 2022
|
29 September 2025
|
| View |
|
BR-1122
|
Rituximab
|
Mabthera
|
1400 mg/ 11.7 mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
Type I USP/Ph. Eur. colourless glass vial sealed
with butyl rubber stopper laminated with fluoro resin film and crimped with an aluminum overseal fitted with a plastic flip-off disk x 15 mL (Box of 1's)
|
-
|
F. Hoffman-La Roche AG
|
Switzerland
|
N/A
|
Roche (Philippines) Inc.
|
Roche (Philippines) Inc.
|
Regular Renewal (Compliance)
|
18 February 2022
|
29 September 2025
|
| View |
|
BR-1123
|
Obinutuzumab
|
Gazyva
|
1 g/40 mL (25mg/mL)
|
Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
Type I Borosilicate glass vial with fluoro resign stopper and aluminum overseal with plastic flip-off disk x 40mL (Box of 1's)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
N/A
|
Roche (Philippines) Inc.
|
Roche (Philippines) Inc.
|
Initial (Variation)
|
12 August 2022
|
12 August 2027
|
| View |
BR-1125_PI_01.pdf
|
BR-1125
|
Quadrivalent Seasonal Influenza Vaccine (Split Virion,
Inactivated) Southern Hemisphere 2024 Strain.
|
Fluarix Tetra
|
Each dose (0.5 mL) contains the following influenza strains*:
A/Victoria/4897/2022 (H1N1)pdm09-like strain
(A/Victoria/4897/2022, IVR-238)
A/Thailand/8/2022 (H3N2)-like strain
(A/Thailand/8/2022, IVR-237)
B/Austria/1359417/2021-like strain
(B/Austria/1359417/2021, BVR-26)
B/Phuket/3073/2013-like strain
(B/Phuket/3073/2013, wild type) [Yamagata lineage] *Propagated in embryonated chicken eggs
**Haemagglutinin
15 μg of HA**
15 μg of HA**
15 μg of HA**
15 μg of HA**
|
Suspension for Injection (IM)
|
Prescription Drug (RX)
|
0.5 mL in 1 mL Type I pre-filled glass syringe with luer lock adapter and plastic rigid tip cap (PRTC) and 2 separate needles (25G 5/8" and 25G 1") in a plastic tray (Box of 1's).
|
Vaccines
|
GlaxoSmithKline Biologicals NL Der SmithKline
|
Germany
|
|
GlaxoSmithKline Philippines, Inc.
|
GlaxoSmithKline Philippines, Inc.
|
Monitored Release (Strain Clearance)
|
19 February 2024
|
19 February 2025
|
| View |
|
BR-1126
|
Secukinumab
|
Cosentyx
|
150 mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1 mL Type I pre-filled glass syringe with grey
bromobutyl rubber plunger stopper, stainless steel 276 12" needle and rubber needle shield, assembled in UltraSafe PassiveTM Needle Guard X100L (Box of l's and 2's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG
|
Switzerland
|
N/A
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Initial (from Monitored Release)
|
12 April 2022
|
06 January 2026
|
| View |
|
BR-1127
|
Secukinumab
|
Scapho
|
150 mg
|
Powder For Solution For Injection (SC)
|
Prescription Drug (RX)
|
6 mL Type I colourless glass vial with grey chlorobutyl rubber stopper and aluminum crimp with white flip-off cap (Box of 1's)
|
Interleukin Inhibitors
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
N/A
|
Sandoz Philippines Corporation
|
Sandoz Philippines Corporation
|
Initial (from Monitored Release)
|
07 April 2022
|
14 January 2026
|
| View |
BR-1130_PI_01.pdf
|
BR-1130
|
Secukinumab
|
Scapho
|
150 mg/mL
|
Solution For Injection (Sc)
|
Prescription Drug (RX)
|
1 mL Type I pre-filled glass syringe with grey
bromobutyl rubber plunger stopper, stainless steel 276 12" needle and rubber needle shield, assembled in an autoinjector pen with transparent window (SensoReady pen) (Box of 1's)
|
-
|
Novartis Pharma Stein AG, Pharmaceutical
|
Switzerland
|
|
Novartis Healthcare Philippines, Inc.
|
Novartis Healthcare Philippines, Inc.
|
Initial (from Monitored Release)
|
11 April 2022
|
06 January 2026
|
| View |
|
BR-1133
|
Pneumococcal Conjugate Vaccine, 13-Valent
(adsorbed) [See formulation on reverse side]
|
Prevenar 13
|
0.5 mL
|
Suspension For Injection (IM)
|
Prescription Drug (RX)
|
Single Dose : 0.5 mL suspension for injection in Becton-Dickinson (BD) Hypak® SCFR Luer-Lok® syringes or Schott SyriQ Luer-Lok® Round Flange pre-filled syringe (Type I Glasss) with separate 25G needle in a Box
|
-
|
Pfizer Ireland Pharmaceuticals
|
Ireland
|
|
Pfizer, Inc.
|
Pfizer, Inc.
|
-
|
10 September 2021
|
21 January 2026
|
| View |
|
BR-1135
|
Chorionic Gonadotrophin
|
Chorapur
|
5000 IU
|
Powder for Injection (IM)
|
Prescription Drug (RX)
|
Type I Glass Vial + 1 mL Type I Glass Ampoule (Diluent: 0.9% Sodium chloride) (Box of 3's)
|
-
|
Ferring GmbH
|
Germany
|
|
Metro Drug, Inc.
|
Metro Drug, Inc.
|
-
|
08 March 2021
|
09 February 2026
|
| View |
|
BR-1138
|
Pembrolizumab
|
Keytruda
|
100mg/4mL (25mg/mL
|
Solution For Injection (IV Infusion)
|
Prescription Drug (RX)
|
In a box of one 10mL Type I glass vial, with a grey chlorobutyl stopper and an aluminum seal with a dark blue flip-off cap
|
Antineoplastic
|
MSD International GmbH T/A MSD Ireland (Carlow)
|
Ireland
|
N/A
|
Merck Sharp & Dohme (I.A) LLC
|
|
Initial
|
06 July 2021
|
17 February 2026
|
| View |
|
BR-1141
|
Rituximab
|
Mabthera
|
10 mg/ mL
|
Concentrate For Solution For Infusion (IV)
|
Prescription Drug (RX)
|
10 mL and 50 mL USP Type I Colorless Glass Vial (Box of 1's)
|
-
|
Roche Diagnostic GmbH
|
Germany
|
|
Roche (Philippines), Inc.
|
Zuellig Pharma Corporation
|
-
|
08 March 2021
|
24 November 2025
|
| View |
|
BR-1148
|
Combined Diphtheria, Tetanus, Acellular Pertussis Vaccine, Adsorbed
|
Boostrix
|
Formulation: 1 dose (0.5 mL) contains:
Diphtheria toxoid*-Not less than 2 IU (2.5Lf) Tetanus toxoid*-Not less than 20 IU (5Lf) Pertussis toxoid (PT)*-8mcg Filamentous Hemagglutinin (FHA)*-8mcg Pertactin-2.5mcg *adsorbed on Aluminum hydroxide, hydrated (Al(OH)3)-300 mcg Al3 and Aluminum phosphate (AlPO4)-200 mcg A13+
|
Suspension For Injection (I.M.)
|
Prescription Drug (RX)
|
0.5 mL Suspension in Type I Glass Vial with Gray Butyl Rubber Stopper and Flip-off Cap (Box of 10's)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
N/A
|
GlaxoSmithKline Philippines, Inc.
|
N/A
|
Renewal
|
27 April 2021
|
03 June 2026
|